Like it or not, short-term profit or not, BPAX is going back over a $1 where it belongs. It was way oversold to begin with and with BioSante now confirming that the LibiGel safety trial will continue as planned, there is no way that we should be at this price level, all things considered.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.